INTRODUCTION Every corner of the human body is inhabited by microbes, collectively known as the microbiome. Thousands of publications over the last decade have described how these microorganisms influence human physiology, health and disease, and […]
Microbiome research promises to transform human health; however, until now the field has been held back by the challenges of translating microbiome data into novel treatments, ingredients, diagnostics, and other healthcare solutions. A number of […]
The composition and metabolic output of the human gut microbiome is shaped by several environmental factors, an important one being diet. To better understand the relationship between diet and microbiome function researchers must develop methods […]
Defining the term “strain” is a conscientious issue within the microbiome field. Broadly speaking, a bacterial strain is a sub-group within a species with unique characteristics such as genetic makeup, metabolism, and morphology. But standards […]
Yeast and bacteria combination for the best of both worlds Yeast and bacteria have been successfully used as probiotic for decades: bacteria, mainly from the Lactobacilli and Bifidobacteria species; and yeast Saccharomyces cerevisiae var. […]
Abstract Microbiome drug development has captured significant interest over the last decade. However, despite the recent clinical and regulatory success stories, this area is lately regarded as a high-risk one by investors given the current […]
Historically, researchers have surveyed the composition and/or expression of microorganisms within the human gut microbiome by collecting fecal samples, isolating microbial nucleic acids, and using those nucleic acids to analyze the microbial species present within […]
Seres Therapeutics, Inc. (Nasdaq: MCRB) and Nestlé Health Science today announced the U.S. Food and Drug Administration (FDA) approval of VOWSTTM (fecal microbiota spores, live-brpk), formerly called SER-109, an orally administered microbiota-based therapeutic to prevent recurrence of C. difficile Infection (CDI) in adults […]
Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that it has raised $106.5 million to support pivotal-stage development of its lead […]
In a step forward for genetic engineering and synthetic biology, researchers have modified a strain of Escherichia coli bacteria to be immune to natural viral infections while also minimizing the potential for the bacteria or their modified […]
In a letter to the National Union of Food Supplements, the Direction générale de la consommation, de la concurrence et de la répression des fraudes (DGCCRF) outlined that supplements can use the term so long […]